Structures by: Daouda B.
Total: 6
2-(2,3-Dihydro-1<i>H</i>-perimidin-2-yl)phenol
C17H14N2O
Acta Crystallographica Section E (2020) 76, 6 798-802
a=9.0710(4)Å b=12.0526(7)Å c=24.6120(11)Å
α=90° β=95.999(4)° γ=90°
2-(2,3-Dihydro-1<i>H</i>-perimidin-2-yl)-6-methoxyphenol
C18H16N2O2
Acta Crystallographica Section E (2020) 76, 5 605-610
a=12.7245(7)Å b=9.5887(6)Å c=23.7276(14)Å
α=90° β=90° γ=90°
3-[2-(3-Methylquinoxalin-2-yloxy)ethyl]-1,3-oxazolidin-2-one
C14H15N3O3
Acta Crystallographica Section E (2010) 66, 5 o1050
a=6.9936(3)Å b=7.6916(3)Å c=13.3709(6)Å
α=86.649(2)° β=77.044(2)° γ=71.141(2)°
3-{2-[(3-Phenylquinoxalin-2-yl)oxy]ethyl}-1,3-oxazolidin-2-one
C19H17N3O3
Acta Crystallographica Section E (2011) 67, 5 o1235
a=10.1392(4)Å b=9.1398(4)Å c=34.8462(15)Å
α=90.00° β=90.00° γ=90.00°
1-Phenyl-3<i>H</i>-2,3-benzodiazepin-4(5<i>H</i>)-one
C15H12N2O
Acta Crystallographica Section E (2012) 68, 8 o2443
a=5.47180(10)Å b=8.40200(10)Å c=26.3250(5)Å
α=90.00° β=90.00° γ=90.00°
3-[2-(3-Phenyl-2-oxo-1,2-dihydroquinoxalin-1-yl)ethyl]-1,3-oxazolidin-2-one
C19H17N3O3
Acta Crystallographica Section E (2013) 69, 5 o662
a=9.6314(5)Å b=16.6596(9)Å c=10.0749(5)Å
α=90.00° β=98.097(3)° γ=90.00°